Allarity Therapeutics Ownership
| ALLR Stock | USD 1.11 0.13 10.48% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Allarity |
Allarity Stock Ownership Analysis
About 12.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.38. Some equities with similar Price to Book (P/B) outperform the market in the long run. Allarity Therapeutics recorded a loss per share of 10.98. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 11th of September 2024. Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts. Allarity Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. For more info on Allarity Therapeutics please contact James JD at 401 426 4664 or go to https://www.allarity.com.Besides selling stocks to institutional investors, Allarity Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Allarity Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Allarity Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Allarity Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 12.0% of Allarity Therapeutics are currently held by insiders. Unlike Allarity Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Allarity Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Allarity Therapeutics' insider trades
Allarity Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Allarity Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Allarity Therapeutics backward and forwards among themselves. Allarity Therapeutics' institutional investor refers to the entity that pools money to purchase Allarity Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Virtu Financial Llc | 2024-06-30 | 265.3 K | Ubs Group Ag | 2024-06-30 | 41.2 K | Hrt Financial Llc | 2024-06-30 | 34.7 K | Jane Street Group Llc | 2024-06-30 | 15.7 K | Tower Research Capital Llc | 2024-06-30 | 12.2 K | Bank Of America Corp | 2024-06-30 | 145 | Headlands Technologies Llc | 2024-09-30 | 0.0 | Jump Financial Llc | 2024-09-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 |
Allarity Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Allarity Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Allarity Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Allarity Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Alexander Epshinsky over two months ago Disposition of tradable shares by Alexander Epshinsky of Allarity Therapeutics subject to Rule 16b-3 |
Allarity Therapeutics Outstanding Bonds
Allarity Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Allarity Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Allarity bonds can be classified according to their maturity, which is the date when Allarity Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Pair Trading with Allarity Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allarity Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allarity Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Allarity Stock
| 0.68 | ELAN | Elanco Animal Health Potential Growth | PairCorr |
Moving against Allarity Stock
| 0.88 | BHC | Bausch Health Companies | PairCorr |
| 0.87 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.82 | GILD | Gilead Sciences | PairCorr |
| 0.72 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.71 | GANX | Gain Therapeutics | PairCorr |
The ability to find closely correlated positions to Allarity Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allarity Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allarity Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allarity Therapeutics to buy it.
The correlation of Allarity Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allarity Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allarity Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allarity Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Allarity Stock Analysis
When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.